NTLA-2003 / Intellia Therap - LARVOL DELTA

Intellia Therapeutics Announces First Quarter 2023 Financial Results and Highlights Recent Company Progress (GlobeNewswire) - "Upcoming Milestones: The Company has set forth the following expected milestones for pipeline progression: NTLA-2002 for HAE: Present additional clinical data from the ongoing first-in-human study of NTLA-2002 in 2023. Complete enrollment in the Phase 2 portion of the Phase 1/2 study in 2H 2023; AATD Franchise: Submit an IND or IND-equivalent application for NTLA-3001 for AATD-associated lung disease in 2H 2023. Complete IND-enabling activities for NTLA-2003 for AATD-associated liver disease by year-end 2023."

IND • P1/2 data • Trial status • Alpha-1 Antitrypsin Deficiency • Genetic Disorders • Hereditary Angioedema